Monday - September 11, 2017

Bayer announces 2017 recipients for the Global Ophthalmology Awards Programme

Over £430,000 awarded in total to 12 ophthalmologists based in the UK, Australia, Belgium, Brazil, Columbia, Japan, the Netherlands and the USA to advance scientific understanding and clinical management of ophthalmic disorders.

Reading, UK, September 11, 2017 – Bayer announced today the 12 recipients of the
2017 Global Ophthalmology Awards Programme (GOAP) at the European Society of
Retina Specialists (EURETINA) Congress 2017, in Barcelona, Spain. Now in its sixth
year, the research and training grants provide support for healthcare professionals
working to improve treatment and disease management for ophthalmology patients
around the world.
The programme’s awards are split into two categories: the Fellowship Project Award is a
mentored award intended to facilitate the development of research and clinical expertise
in the field of retina. Awarded to applicants who have completed their ophthalmology
training, this grant provides funding for those that wish to work on a specific research
project as part of their training to become a retinal specialist. The second award, the
Research Award, supports a wide range of basic and/or clinical research projects in
retinal diseases, including diagnosis and assessment, treatment, surgery, quality of life
and mechanisms of action.
This year’s twelve recipients of the GOAP include researchers and clinicians based
across eight different countries, reflecting the truly global nature of this program:


Fellowship Project Awards
Mital Shah, Oxford Eye Hospital, Oxford, UK
Project title: Understanding cone degeneration in retinitis pigmentosa using highresolution
retinal imaging


Jose Ronaldo Carvalho, Eye Institute, University of Columbia, New York, USA
Project title: Optimizing prognostication for bestrophin retinal dystrophy using multi-modal

Jorge Andres Orellana-Rios, New York University School of Medicine, New York, USA
Project title: Validated autoflourescence in age-related macular degeneration

Hernan Andres Rios Calixto, Fundacion Oftalmologica Nacional, Colombia
Project title: Neural networks for detection of diabetic retinopathy and diabetic macular


Research Awards
Anouk Georges, University Hospital of Liège, Belgium
Project title: In vitro modulating retinal synaptogenesis as strategy to enhance functional
recovery upon transplantation

Robyn Guymer, Centre for Eye Research Australia, Melbourne, Australia
Project title: Improving visual outcomes for neovascular AMD using tablet-based
monitoring in the home

Caspar Jonker, Margaret M. Dyson Vision Research Institute, Weill Cornell Medicine,
New York, USA
Project title: Generation of an in vitro model of retina & choroid to study and screen drugs
for blinding diseases

Atsuhiro Kanda, Department of Ophthalmology Faculty of Medicine and Graduate School
of Medicine Hokkaido University, Hokkaido, Japan
Project title: Crosstalk between glycans and their binding partners in the pathogenesis of
diabetic retinopathy

Ingeborg Klaassen, Academic Medical Center, Amsterdam, Netherlands
Project title: The role of PLVAP in the treatment of DME

Hetian Lei, Schepens Eye Research Institute of Massachusetts Eye and Ear, Department
of Ophthalmology, Harvard Medical School, USA
Project title: PI3K and pathological retinal angiogenesis

Hidetaka Matsumoto, Department of Ophthalmology, Gunma University School of
Medicine, Gunma, Japan
Project title: The role of TRPV4 in photoreceptor cell death after retinal detachment

Steven Yeh, Emory Eye Center, Emory University, Atlanta, USA
Project title: Serologic and Molecular Diagnosis of Infectious Uveitis in a Viral
Hemorrhagic Fever Zone

“Bayer is deeply committed to advancing the state of care in ophthalmology. We are
delighted that the GOAP pursues its aim to contribute to research to improve
understanding of disease mechanisms and develop new treatments for eye diseases and
that since the programme’s induction six years ago there has been a UK recipient of the
award each year.” said Dr Jackie Napier, Medical Director of Ophthalmology, Bayer.

A group of prominent healthcare professionals working within ophthalmology form the
Grants Review and Awards Committee (GRAC) and make the award decisions based on
the applicants’ merit and eligibility. The GRAC works independently of Bayer in reviewing
applications and is co-chaired by leading medical retinal specialists, Dr. Jennifer Arnold
(Australia) and Professor Quan Dong Nguyen (USA). The group also comprises other
leading international ophthalmologists: Professor Francesco Bandello (Italy), Dr. Patricia
D’Amore (USA), Mr. Phil Hykin (UK), Dr. Peter Kertes (Canada), Dr. William Li (USA),
Professor Pascale Massin (France), Professor Masahito Ohji (Japan), Professor Calvin
Pang (Hong Kong), Professor Daniel Pauleikhoff (Germany), Dr. Francisco Rodríguez
(Colombia), and Professor Tien Yin Wong (Singapore).

“The GOAP offers us a unique opportunity to recognise and assist talented and inspiring
researchers in advancing the understanding and management of ophthalmic disorders. All
of us on the Grants Review and Awards Committee are continually impressed with the
exceptional quality of scientific proposals and the caliber of applicants we see for this
program. We congratulate this year’s winners, and all applicants, for their dedication to
influencing the field of ophthalmology, and look forward to reviewing the applications for

the 2018 awards,” said the GRAC Co-Chairs, Dr Jennifer Arnold and Professor Quan
Dong Nguye

About GOAP
GOAP aims to advance the scientific understanding and clinical management of retinal
ophthalmic disorders. Through research and training grants, the programme seeks to
provide opportunities for ophthalmology healthcare professionals that will ultimately lead
to improved treatment and management for the world’s ophthalmology patients.

Since 2012, Bayer has awarded more than £2.1 million to 58 recipients to further advance
research and care in ophthalmology through the GOAP.

Applications to the programme are encouraged throughout the year; the next deadline for
receiving Letters of Intent (LOI) is 30 March 2018. Please visit the website for more
details about the application process, as well as other important information:www.bayer-ophthalmology-

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health
care and agriculture. Its products and services are designed to benefit people and
improve their quality of life. At the same time, the Group aims to create value through
innovation, growth and high earning power. Bayer is committed to the principles of
sustainable development and to its social and ethical responsibilities as a corporate
citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR
46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7
billion. These figures include those for the high-tech polymers business, which was
floated on the stock market as an independent company named Covestro on October 6,
2015. For more information, go to